The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease

Kaczmarek, Przemysław; Sładek, Krzysztof; Skucha, Wojciech; Rzeszutko, Marcin; Iwaniec, Teresa; Dziedzina, Sylwia; Szczeklik, Andrzej

doi:10.20452/pamw.869

Cited by 20 publications

(22 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as JUPITER included a high proportion of obese patients, the characteristics of the participants may not be representative of a population with stable COPD, and therefore, the results cannot be extrapolated to this population. Moreover, two previously reported clinical trials in patients with COPD have demonstrated inconsistent results [25,26].…”

Section: Effect Of Rosuvastatin Treatment In Stable Copdmentioning

confidence: 99%

Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial

et al. 2015

View full text Add to dashboard Cite

Abstract. Neukamm A, Høiseth AD, Einvik G, Lehmann S, Hagve T-A, Søyseth V, Omland T (Akershus University Hospital, Lørenskog; Center for Heart Failure Research and KG Jebsen Cardiac Research Centre, University of Oslo, Oslo; Akershus University Hospital, Lørenskog; Haukeland University Hospital, Bergen; University of Bergen, Bergen; Akershus University Hospital, Lørenskog, Norway). Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J Intern Med 2015; 278: 59-67.Objectives. The objective of this study was to examine whether statin therapy is associated with enhanced endothelium-dependent vascular function, improved pulmonary function and reduced systemic inflammation in patients with chronic obstructive pulmonary disease (COPD).Design and setting. This randomized, placebo-controlled, double-blind, parallel trial including patients with COPD was performed at two University hospitals in Norway.Subjects, intervention and measurements. Patients with stable COPD (n = 99) were assigned randomly to receive rosuvastatin 10 mg (n = 49) or matching placebo (n = 50) once daily for 12 weeks. The primary outcome measure was change in endothelium-dependent vascular function measured using peripheral arterial tonometry and expressed as the reactive hyperaemia index. Secondary end-points were change in pulmonary function, as assessed by forced expiratory volume in 1 s (FEV1) and FEV1/ forced vital capacity (FVC), and change in the circulating levels of the inflammatory markers interleukin-6 (IL6) and high-sensitivity C-reactive protein (hsCRP).Results. In the overall study population, no significant between-group difference in change in endothelium-dependent vascular or pulmonary function was observed. Rosuvastatin therapy was associated with a reduction in hsCRP (À20% vs. 11%, P = 0.017) and an attenuation of the rise in IL6 concentration (8% vs. 30%, P = 0.028) compared with placebo. In a prespecified subgroup analysis of patients with a supra-median circulating hsCRP concentration (>1.7 mg L À1 ), rosuvastatin was associated with improved endotheliumdependent vascular function (13% vs. 2%, P = 0.026).Conclusions. In stable COPD patients without the standard indications for statin therapy, rosuvastatin treatment is associated with a significant attenuation of systemic inflammation and improvement in endothelial-dependent vascular function in patients with evidence of systemic inflammation.

show abstract

Section: Effect Of Rosuvastatin Treatment In Stable Copdmentioning

confidence: 99%

Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In contrast to the findings of this study, Kaczmarek found no differences in the level of circulating inflammatory markers after a 3-month treatment with statin. The difference between the findings of the mentioned studies are because of non-comparable sample size and genetic differences in study populations or the inclusion of COPD patients with pulmonary hypertension [30,40].…”

Section: Discussionmentioning

confidence: 96%

The Effect of Atorvastatin on Right Ventricular Function in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

Poorzand¹,

Rezaeetalab²,

Sadeghipour³

et al. 2018

Int J Respir Pulm Med

View full text Add to dashboard Cite

Objective: Inflammation has an important role in chronic obstructive pulmonary diseases (COPD) and statins are believed to have anti-inflammatory effects beyond low-density lipoprotein cholesterol reduction. This study aimed to assess the effect of statin on the function of the right ventricle and inflammatory markers in COPD patients. Methods: A total of 76 clinically stable COPD patients were included in this randomized, double-blind study. Patients were randomly assigned to receive atorvastatin (40 mg/d) or a placebo over a period of three months. All the patients underwent spirometry, echocardiography, and high-sensitivity C-reactive protein (hsCRP) measurement at baseline and at the end of the study. Right ventricular (RV) systolic function was assessed by echocardiography using the systolic velocity of tricuspid annulus (Sm) and longitudinal strain in the base and mid segments of RV free wall (SRB, SRM). Pulmonary artery pressure (PAP) was estimated by the tricuspid regurgitation gradient. Results: Fifty-five patients (31 in atorvastatin and 24 in the placebo group) completed the course of intervention. Atorvastatin resulted in improvement in RVSB (p = 0.03) and decrease in hsCRP (p = 0.03) compared to placebo group while RV SRM was significantly improved in atorvastatin group (p = 0.01) but this change was not significant between groups (p = 0.44). Conclusion: Statins could improve the prognosis in COPD patients by improving right ventricular hemodynamic.

show abstract

“…Many studies had previously shown the anti-in ammatory effect of statin (23,24), but few studies could not demonstrate this effect (25,26). Considering the signi cant reduction in serum cholesterol level in Atorvastatin group it is unlikely that poor adherence to the study protocol could explain the failure to reach statistical difference between groups.…”

Section: Discussionmentioning

confidence: 96%

“…Therefore, larger prospective randomized controlled trials with long time follow up with focusing on the respiratory tract indices, like exhaled air condensate or bronchoalveolar lavage, both during stable periods and exacerbations (25) and/or other systemic in ammatory such as monocyte-macrophage function(23) is needed on the patients with chronic bronchitis due to sulfur mustard gas inhalation.…”

Section: Limitationsmentioning

confidence: 99%

The Effect of Atrovastatin on Inflammatory Markers in Sulfur Mustard Gas Induced Bronchitis; A Randomized Double-Blinded, Placebo-Controlled Clinical Trial

Momeni

Nazer

Masoompour

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: This study was conducted to evaluate the anti-inflammatory effect of atorvastatin in patients with chronic bronchitis due to sulfur mustard gas inhalation. Methods: In this randomized double-blinded clinical trial we enrolled patients with chronic bronchitis due to sulfur mustard gas inhalation. Ninety man aged between 45 to 75 years with diagnosed of chronic bronchitis due to exposure to mustard gas during the Iran-Iraq war, were randomly assigned to receive either atorvastatin (40 mg) or placebo, given orally once a day for 3 months. The interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), procalcitonin, highly sensitive CRP, and COPD assessment test (CAT) score in both groups compared with each other and baseline data. Results: After 12 weeks of using atorvastatin (n=40), the level IL-6 decreased significantly (p=0.03) without any significant differences in the level of TNF-α, high sensitive CRP, and procalcitonin (P=0.31, p=0.78, and p=0.08). In placebo group (n=38), both procalcitonin and IL-6 significantly decreased after 12 weeks (P=0.002 and p<0.001), but levels of high sensitive CRP did not differ significantly and the level of TNF-α increased (p=0.006). The mean differences in levels of TNF- α, IL-6, high sensitive CRP, and procalcitonin did not differ statistically significant between the study groups after 12 weeks. Although after 12 weeks of study in both groups the CAT score have had appreciably high magnitude decrease (P<0.001), but its mean differences change wasn't significant between group (P=0.71). Conclusions: Administration of 40 mg atorvastatin for 3 months although could not significantly change systemic inflammatory markers or quality of life in mustard gas induced chronic bronchitis.Trial registration: IRCT, IRCT138904144312N1. Registered 16 August 2014, https://en.irct.ir/trial/4577

show abstract

The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease

Cited by 20 publications

References 1 publication

Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial

Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial

The Effect of Atorvastatin on Right Ventricular Function in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

The Effect of Atrovastatin on Inflammatory Markers in Sulfur Mustard Gas Induced Bronchitis; A Randomized Double-Blinded, Placebo-Controlled Clinical Trial

Contact Info

Product

Resources

About